Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients.

Outcomes following hepatitis C virus (HCV)-viremic heart transplantation into HCV-negative recipients with HCV treatment are good. We assessed cost-effectiveness between cohorts of transplant recipients willing and unwilling to receive HCV-viremic hearts. Markov model simulated long-term outcomes among HCV-negative patients on the transplant waitlist.

Outcomes of heart transplantation from hepatitis C virus-positive donors.

Background: National data demonstrate that increasing opportunities exist for organ donation among hepatitis C virus (HCV)-infected individuals.

Methods: We developed a clinical practice protocol for the acceptance of HCV+ organs for HCV- patients who underwent heart transplantation (HT) and retrospectively reviewed the outcomes at our institution. Inclusion criteria were as follows: all adult patients listed for HT.